|
MechanismDNA intercalators |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.United States |
First Approval Date02 Feb 1977 |
Target- |
MechanismApoptosis stimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.
100 Clinical Results associated with Key Pharmaceuticals, Inc.
0 Patents (Medical) associated with Key Pharmaceuticals, Inc.
100 Deals associated with Key Pharmaceuticals, Inc.
100 Translational Medicine associated with Key Pharmaceuticals, Inc.